Xeris Pharmaceuticals Scheduled to Report Q3 2026 Earnings on November 5
Xeris Pharmaceuticals (XERS) is set to release its third-quarter 2026 financial results on Thursday, November 5, prior to the market opening. Investors are closely watching for performance metrics that reflect the company's recent growth trajectory. Market consensus estimates project an earnings per share (EPS) of $0.03 and total revenue of approximately $101.68 million. The projected revenue represents a significant year-over-year increase of 36.7%, signaling strong top-line momentum for the pharmaceutical company.
